## Overview
Insomnia is the persistent difficulty initiating sleep, maintaining sleep, or waking too early with an inability to return to sleep, despite adequate opportunity and circumstances for rest. It is classified under ICD-10 code **G47.00** (Insomnia, unspecified) and is one of the most prevalent sleep–wake disorders worldwide.
Insomnia affects an estimated **30–35 %** of the general adult population when defined by nocturnal symptoms alone, and roughly **10–15 %** of adults meet criteria for chronic insomnia disorder — defined as symptoms occurring at least three nights per week for three months or longer [1][2]. Women are approximately 1.4 times more likely to experience insomnia than men, and prevalence rises steadily with age [2].
People search for information on insomnia because it profoundly impacts daytime functioning: fatigue, impaired concentration, mood disturbance, reduced work productivity, and increased accident risk are all well-documented consequences. Chronic insomnia is also independently associated with higher risk of depression, anxiety disorders, cardiovascular disease, and type 2 diabetes [1]. Understanding its causes and evidence-based management is therefore essential.
---
## Common Causes
Insomnia is rarely a standalone condition. It typically arises from — or is perpetuated by — one or more of the following mechanisms, listed roughly by frequency in primary care populations.
### 1. Psychophysiological (Learned) Insomnia
The most common form in otherwise healthy adults. A triggering stressor (job loss, bereavement, illness) initiates poor sleep, which then becomes self-perpetuating through conditioned arousal: the bed becomes associated with wakefulness and anxiety about sleep rather than sleep itself. Heightened cognitive and somatic hyperarousal at bedtime maintains the cycle even after the original stressor resolves [1].
### 2. Psychiatric and Mood Disorders
Depression, generalized anxiety disorder, PTSD, and bipolar disorder are strongly comorbid with insomnia. The relationship is bidirectional — insomnia increases the risk of developing depression by roughly twofold, and depression worsens sleep architecture through dysregulation of serotonergic and noradrenergic pathways [3].
### 3. Poor Sleep Hygiene and Behavioral Factors
Irregular sleep–wake schedules, excessive screen time before bed (blue-light–mediated melatonin suppression), caffeine or alcohol use within 6 hours of bedtime, and daytime napping longer than 20–30 minutes all disrupt the homeostatic sleep drive and circadian timing.
### 4. Medical Conditions
Chronic pain (arthritis, fibromyalgia), gastroesophageal reflux disease (GERD), chronic obstructive pulmonary disease (COPD), heart failure (paroxysmal nocturnal dyspnea), hyperthyroidism, restless legs syndrome (RLS), and nocturia are frequent medical contributors. Each disrupts sleep through distinct physiological pathways — for example, RLS involves dopaminergic dysfunction in the basal ganglia that produces uncomfortable limb sensations at rest [1].
### 5. Medications and Substances
Common offenders include stimulants (methylphenidate, modafinil), certain antidepressants (SSRIs, SNRIs — especially fluoxetine and venlafaxine), beta-blockers, corticosteroids, theophylline, and decongestants containing pseudoephedrine. Withdrawal from benzodiazepines, opioids, or alcohol is another well-recognized trigger.
### 6. Circadian Rhythm Disorders
Delayed sleep–wake phase disorder (common in adolescents and young adults), advanced sleep–wake phase disorder (common in older adults), shift-work disorder, and jet lag all produce insomnia symptoms by misaligning the endogenous circadian clock with the desired sleep window.
### 7. Primary Sleep Disorders
Obstructive sleep apnea (OSA) can present with insomnia-predominant symptoms — particularly in women — and should always be considered when insomnia is refractory to standard therapy [4].
---
## RED FLAGS
Most insomnia is not a medical emergency. However, seek **immediate medical attention (ER / 911)** if insomnia is accompanied by any of the following:
- **Active suicidal ideation or self-harm thoughts** — insomnia is an independent risk factor for suicidality
- **Chest pain, severe shortness of breath, or heart palpitations** during the night (may indicate cardiac or pulmonary emergency)
- **Sudden-onset confusion, disorientation, or altered consciousness** — consider delirium, especially in elderly patients
- **Severe withdrawal symptoms** (tremors, seizures, hallucinations) after stopping alcohol, benzodiazepines, or barbiturates
- **New-onset insomnia with severe headache, neck stiffness, fever, and photophobia** — consider meningitis or encephalitis
- **Symptoms of a hyperthyroid crisis (thyroid storm)**: rapid heart rate, high fever, agitation, and inability to sleep
- **Bizarre behaviors during sleep** (violent movements, screaming, walking) that risk injury — may indicate REM sleep behavior disorder or nocturnal seizures
---
## Self-Care at Home
Non-pharmacological interventions are recommended as **first-line therapy** for chronic insomnia by the American College of Physicians (ACP), the American Academy of Sleep Medicine (AASM), and the European Sleep Research Society [3][4][5].
### Cognitive Behavioral Therapy for Insomnia (CBT-I)
CBT-I is the gold-standard non-drug treatment. A 2015 systematic review and meta-analysis found that CBT-I produces clinically meaningful improvements in sleep onset latency (−19 min), wake after sleep onset (−26 min), and sleep efficiency (+10 %) that are durable at 12-month follow-up [5]. Components include:
- **Sleep restriction therapy** — limiting time in bed to match actual sleep duration, then gradually extending it
- **Stimulus control** — using the bed only for sleep and intimacy; leaving bed if unable to sleep within ~20 minutes
- **Cognitive restructuring** — challenging catastrophic beliefs about sleeplessness
- **Relaxation training** — progressive muscle relaxation, diaphragmatic breathing, or guided imagery
CBT-I can be delivered in-person, by telehealth, or via validated digital platforms (e.g., FDA-cleared Somryst/Pear-004).
### Sleep Hygiene Practices
While insufficient as standalone therapy for chronic insomnia, these measures support other interventions:
- Maintain a consistent wake time 7 days per week (anchor the circadian clock)
- Keep the bedroom cool (approximately 18–20 °C / 65–68 °F), dark, and quiet
- Avoid screens for at least 30–60 minutes before bed, or use blue-light–filtering settings
- Limit caffeine intake after noon; avoid alcohol within 3–4 hours of bedtime
- Exercise regularly (≥ 150 min/week moderate aerobic activity), but avoid vigorous exercise within 2 hours of bedtime
- Avoid large meals close to bedtime; a light snack may be acceptable
- Limit daytime naps to ≤ 20 minutes before 3 PM
### Additional Evidence-Based Approaches
- **Mindfulness-based stress reduction (MBSR)** and **mindfulness meditation** have shown moderate improvements in sleep quality in randomized trials
- **Regular physical activity** — a meta-analysis demonstrated that consistent aerobic exercise improves sleep quality with an effect size comparable to pharmacotherapy [6]
- **Bright-light therapy** in the morning (10,000 lux for 20–30 min) may benefit those with circadian misalignment
---
## OTC Medications That Help
Over-the-counter options are generally intended for **short-term, occasional** use only. They should not be used as long-term monotherapy for chronic insomnia without clinician guidance.
| Class | Example | Typical Adult Dose | Notes |
|---|---|---|---|
| **Antihistamines (first-generation H₁ blockers)** | Diphenhydramine (e.g., Benadryl, ZzzQuil) | 25–50 mg at bedtime | Anticholinergic side effects (dry mouth, urinary retention, constipation). Tolerance develops within 3–7 days. Avoid in elderly (Beers Criteria). May impair next-day performance. |
| **Antihistamines (first-generation H₁ blockers)** | Doxylamine (e.g., Unisom SleepTabs) | 25 mg at bedtime | Similar profile to diphenhydramine. Slightly longer half-life (~10 h); greater risk of morning sedation. Avoid in elderly. |
| **Melatonin (exogenous)** | Melatonin (various brands) | 0.5–5 mg, 30–60 min before bedtime | Most effective for circadian rhythm disorders and jet lag. Evidence for primary insomnia is modest. Start with the lowest effective dose (0.5–1 mg). Generally well-tolerated. Not strictly regulated by the FDA (sold as a supplement); product quality may vary. |
| **L-Tryptophan / 5-HTP** | Various supplements | 500 mg L-tryptophan or 100–300 mg 5-HTP | Precursor to serotonin and melatonin. Limited high-quality evidence. Avoid combining with serotonergic drugs (risk of serotonin syndrome). |
| **Valerian root** | Valeriana officinalis extract | 300–600 mg, 30 min–2 h before bed | Mechanism unclear; may modulate GABA receptors. Cochrane review found inconsistent evidence for insomnia. Generally safe short-term; may cause headache or GI upset. |
| **Magnesium** | Magnesium glycinate or citrate | 200–400 mg at bedtime | May help if magnesium-deficient. Acts on GABA receptors and NMDA pathways. Loose stools at higher doses (especially oxide form). Avoid in severe renal impairment. |
> **Important:** OTC sleep aids are not appropriate for everyone. Individuals with glaucoma, urinary retention, prostate enlargement, or those taking MAO inhibitors should consult a pharmacist or clinician before using antihistamine-based products.
---
## Prescription Options
Prescription medications are generally reserved for patients who do not respond adequately to CBT-I or who require adjunctive short-term pharmacotherapy. The AASM clinical practice guideline [4] and ACP guideline [3] recommend shared decision-making between clinician and patient.
| Class | Examples | Mechanism | Notes |
|---|---|---|---|
| **Dual orexin receptor antagonists (DORAs)** | Suvorexant (Belsomra) 10–20 mg; Lemborexant (Dayvigo) 5–10 mg | Blocks wake-promoting orexin (hypocretin) signaling | Preferred by AASM for sleep-onset and sleep-maintenance insomnia. Lower abuse potential than benzodiazepine-receptor agonists. May cause next-day somnolence. Schedule IV controlled substance. |
| **Melatonin receptor agonists** | Ramelteon (Rozerem) 8 mg | Selective MT₁/MT₂ receptor agonist | FDA-approved for sleep-onset difficulty. No abuse potential (not a controlled substance). Safe in elderly. May be less effective for sleep maintenance. |
| **Non-benzodiazepine hypnotics ("Z-drugs")** | Zolpidem (Ambien) 5–10 mg; Eszopiclone (Lunesta) 1–3 mg; Zaleplon (Sonata) 5–10 mg | Selective GABA-A receptor modulation (α₁ subunit) | Effective short-term. Risk of complex sleep behaviors (sleepwalking, sleep-driving) — FDA black-box warning added in 2019. Tolerance and dependence possible. Lower starting doses recommended for women (zolpidem 5 mg) and elderly. Schedule IV. |
| **Benzodiazepines** | Temazepam (Restoril) 7.5–30 mg; Triazolam (Halcion) 0.125–0.25 mg | Non-selective GABA-A receptor agonism | Generally not first-line due to dependence, tolerance, rebound insomnia, and fall risk. May be appropriate short-term when other agents fail. Schedule IV. Avoid abrupt discontinuation. |
| **Low-dose sedating antidepressants** | Trazodone 25–100 mg; Doxepin (Silenor) 3–6 mg | 5-HT₂A antagonism + H₁ blockade (trazodone); selective H₁ antagonism at low dose (doxepin) | Trazodone is widely prescribed off-label but has limited RCT evidence for primary insomnia. Doxepin 3–6 mg is FDA-approved specifically for sleep-maintenance insomnia and is well-studied in elderly populations. |
| **Gabapentinoids** | Gabapentin 100–300 mg (off-label) | Modulates α₂δ voltage-gated calcium channels | May be useful when insomnia coexists with chronic pain, RLS, or anxiety. Not FDA-approved for insomnia. Risk of sedation and dizziness. |
> **Prescribing context:** Primary care physicians, psychiatrists, and sleep medicine specialists may prescribe these agents. A sleep study (polysomnography) may be required before initiating certain treatments to rule out obstructive sleep apnea or other primary sleep disorders.
---
## Lab Tests Typically Ordered
Insomnia is primarily a clinical diagnosis based on history. However, targeted laboratory evaluation is often pursued to identify underlying or contributing conditions.
| Test | Rationale |
|---|---|
| **Thyroid function panel (TSH, free T₄)** | Hyperthyroidism and hypothyroidism both disrupt sleep architecture. [See /tests/thyroid-function-panel] |
| **Complete blood count (CBC)** | Screen for anemia (which may cause restless legs syndrome) and underlying infection or inflammation. [See /tests/complete-blood-count] |
| **Iron studies (serum ferritin, TIBC)** | Ferritin < 50–75 µg/L is associated with restless legs syndrome, a common insomnia mimic. [See /tests/iron-studies] |
| **Comprehensive metabolic panel (CMP)** | Assess renal function (uremia can disrupt sleep), hepatic function, glucose (uncontrolled diabetes may cause nocturia), and electrolytes (magnesium, calcium). [See /tests/comprehensive-metabolic-panel] |
| **Hemoglobin A1c** | Screen for diabetes if nocturia or peripheral neuropathy is contributing to sleep disruption. [See /tests/hemoglobin-a1c] |
| **Cortisol level (morning or 24-hour urinary free cortisol)** | If Cushing syndrome is suspected (insomnia with weight gain, striae, hypertension). [See /tests/cortisol-level] |
| **Polysomnography (PSG)** | Gold-standard sleep study when obstructive sleep apnea, periodic limb movement disorder, narcolepsy, or parasomnias are suspected — particularly if insomnia is treatment-refractory. [See /tests/polysomnography] |
| **Actigraphy** | Wrist-worn device tracking rest–activity patterns over 1–2 weeks. Useful for circadian rhythm disorders and to objectively estimate sleep parameters when PSG is not indicated. |
| **PHQ-9 / GAD-7 screening** | Validated questionnaires for depression and anxiety, the two most common psychiatric comorbidities driving insomnia. |
---
## Special Populations
### Children and Adolescents
Behavioral insomnia of childhood (sleep-onset association type and limit-setting type) is common in children aged 1–5 years. **Behavioral interventions** (graduated extinction, positive bedtime routines) are first-line and have strong evidence [7]. Pharmacotherapy is generally not recommended in pediatric populations, and no hypnotic medications are FDA-approved for children. If melatonin is considered (e.g., for circadian delay in adolescents or children with autism spectrum disorder), it should only be used under the guidance of a pediatrician or pediatric sleep specialist at the lowest effective dose. **Do not administer OTC antihistamines for sleep in children under 6 years without explicit medical advice**, as paradoxical excitation and anticholinergic toxicity are concerns.
### Pregnancy
Insomnia is reported by up to 75 % of pregnant women, particularly in the third trimester. Non-pharmacological approaches (CBT-I, sleep hygiene) are strongly preferred.
- **Melatonin:** Limited human safety data in pregnancy; generally not recommended (no FDA pregnancy category under the new labeling system, but animal data raise some concern)
- **Diphenhydramine:** Generally considered compatible with pregnancy (former FDA Category B); may be used short-term under obstetric guidance
- **Doxylamine:** Combined with pyridoxine (vitamin B₆), it is FDA-approved for nausea in pregnancy (Diclegis/Bonjesta) and has an extensive safety record; its sedating effect may secondarily help sleep
- **Benzodiazepines and Z-drugs:** Generally avoided, especially in the first trimester (potential teratogenicity) and near delivery (neonatal sedation, withdrawal); use only if benefits clearly outweigh risks per ACOG guidance
- **Ramelteon:** Insufficient human data; not recommended in pregnancy
- **Suvorexant / lemborexant:** Insufficient human data; not recommended in pregnancy
Consult an obstetrician before initiating any pharmacotherapy for insomnia during pregnancy or breastfeeding.
### Elderly (≥ 65 Years)
Older adults are disproportionately affected by insomnia due to age-related changes in circadian rhythm amplitude, increased medical comorbidities, polypharmacy, and reduced slow-wave sleep.
- **CBT-I remains first-line** and is effective in this population [3]
- **Avoid first-generation antihistamines** (diphenhydramine, doxylamine) — listed on the American Geriatrics Society Beers Criteria due to anticholinergic burden, cognitive impairment, fall risk, and delirium
- **Avoid benzodiazepines** when possible (Beers Criteria) — increased risk of falls, hip fractures, and cognitive decline
- **Low-dose doxepin (3–6 mg)** is FDA-approved and studied specifically in older adults for sleep-maintenance insomnia
- **Ramelteon** is considered safe in elderly patients (no abuse potential, minimal next-day impairment)
- **Suvorexant** should be started at the lowest dose (10 mg) in elderly patients
- If Z-drugs are used, **start at the lowest dose** (e.g., zolpidem 5 mg) and limit duration
### Athletes
Athletes frequently experience insomnia due to pre-competition anxiety, travel across time zones, early-morning training schedules, and overtraining syndrome.
- CBT-I and sleep hygiene are first-line
- **Melatonin** (0.5–3 mg) is generally permitted under World Anti-Doping Agency (WADA) rules and is useful for jet lag in traveling athletes
- **Antihistamines** may impair next-day reaction time and motor performance — use with caution
- **Z-drugs and benzodiazepines** are not prohibited by WADA but may impair performance and are subject to anti-doping therapeutic use exemption considerations
- Athletes should consult both a sports medicine physician and their sport's anti-doping authority before using any sleep medication
---
## When to Escalate
Use the following thresholds to determine the urgency of medical evaluation:
### Same-Day General Practitioner (GP) Appointment
- Insomnia lasting more than 4 weeks despite consistent sleep-hygiene improvements
- Insomnia newly associated with mood changes, anxiety, or impaired work/school performance
- Suspicion of medication-induced insomnia (new medication started recently)
- Symptoms suggestive of restless legs syndrome or periodic limb movements
- Snoring, witnessed apneas, or excessive daytime sleepiness (evaluate for OSA)
### Urgent Care (Within 24–48 Hours)
- Severe insomnia with significant functional impairment (inability to work, drive safely, or care for dependents)
- Insomnia following abrupt discontinuation of a prescribed sedative (risk of withdrawal)
- New-onset insomnia with fever, weight loss, or night sweats (evaluate for infection, malignancy, or endocrine disorder)
### Emergency Room / 911
- Insomnia accompanied by **suicidal thoughts, self-harm urges, or psychotic symptoms** (hallucinations, paranoia)
- Signs of **alcohol or benzodiazepine withdrawal** (tremors, tachycardia, seizures, delirium tremens)
- Insomnia with **acute chest pain, severe dyspnea, or signs of stroke** (sudden-onset neurological deficits)
- **Delirium** (acute confusion, disorientation, fluctuating consciousness) — especially in elderly or hospitalized patients
> **General principle:** If insomnia is causing significant distress or functional impairment, do not hesitate to seek medical evaluation. Early intervention — particularly with CBT-I — yields the best long-term outcomes.
---
## References
[1] Morin CM, Drake CL, Harvey AG, et al. Insomnia disorder. *Nat Rev Dis Primers*. 2015;1:15026. PMID:27189779.
[2] Roth T. Insomnia: definition, prevalence, etiology, and consequences. *J Clin Sleep Med*. 2007;3(5 Suppl):S7–S10. PMID:17824495.
[3] Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2016;165(2):125–133. PMID:27136449.
[4] Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med*. 2017;13(2):307–349. PMID:27998379.
[5] Trauer JM, Qian MY, Doyle JS, Rajaratnam SMW, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. *Ann Intern Med*. 2015;163(3):191–204. PMID:26054060.
[6] Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. *J Sleep Res*. 2017;26(6):675–700. PMID:28125141.
[7] Buysse DJ. Insomnia. *JAMA*. 2013;309(7):706–716. PMID:23423416.
---
*This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment decisions. Content reviewed April 2026.*
